NIFTY 50

Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization

Updated : November 18, 2020 08:29 PM IST

Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94 percent.
Vaccine was well-tolerated and that side effects were mostly mild to moderate, claims the company.

You May Also Like

Live TV

recommended for you